AGMB ▼ -6.0% - AgomAb Therapeutics NV $AGMB - Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study AgomAb Therapeutics shares fell 6.0% despite the company announcing positive Phase 1 results for its lead candidate AGMB-447 in idiopathic pulmonary fibrosis patients and outlining a Phase 2 study design. The decline suggests investors may have concerns about the commercial path forward, trial design details, or broader market conditions that outweighed enthusiasm for the early-stage efficacy data. 14-SEP-2026 04:05 PM ET